Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
MediciNova Inc (MNOV)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: MNOV (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7
1 Year Target Price $7
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -20.83% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 63.76M USD | Price to earnings Ratio - | 1Y Target Price 7 |
Price to earnings Ratio - | 1Y Target Price 7 | ||
Volume (30-day avg) 2 | Beta 0.35 | 52 Weeks Range 1.13 - 2.55 | Updated Date 08/15/2025 |
52 Weeks Range 1.13 - 2.55 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.23 |
Earnings Date
Report Date 2025-08-13 | When - | Estimate -0.095 | Actual -0.07 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -13.81% | Return on Equity (TTM) -20.33% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 27378513 | Price to Sales(TTM) 82.89 |
Enterprise Value 27378513 | Price to Sales(TTM) 82.89 | ||
Enterprise Value to Revenue 38.74 | Enterprise Value to EBITDA -2.65 | Shares Outstanding 49046200 | Shares Floating 42081189 |
Shares Outstanding 49046200 | Shares Floating 42081189 | ||
Percent Insiders 2.98 | Percent Institutions 22.02 |
Upturn AI SWOT
MediciNova Inc
Company Overview
History and Background
MediciNova, Inc. was founded in 2000. It is a biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs, primarily neurological disorders, inflammatory diseases, and cancer.
Core Business Areas
- Neurological Disorders: Development of MN-166 (ibudilast) for neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS) and progressive multiple sclerosis (PMS).
- Inflammatory Diseases: Research into MN-001 (tipelukast) for idiopathic pulmonary fibrosis (IPF) and nonalcoholic steatohepatitis (NASH).
- Cancer: Evaluation of MN-166 in various cancer indications, including glioblastoma.
Leadership and Structure
The company is led by Yuichi Iwaki, M.D., Ph.D., President and CEO. The organizational structure includes departments for research and development, clinical trials, and corporate functions.
Top Products and Market Share
Key Offerings
- MN-166 (Ibudilast): A phosphodiesterase inhibitor and macrophage migration inhibitory factor (MIF) inhibitor. Currently in clinical development for ALS, PMS, and other neurological indications. Market share is not applicable as it is not currently approved in any market. Competitors include Mitsubishi Tanabe Pharma (Radicava/edaravone) and Amylyx Pharmaceuticals (Relyvrio).
- MN-001 (Tipelukast): A leukotriene receptor antagonist in development for IPF and NASH. Market share is not applicable as it is not currently approved in any market. Competitors in the IPF market include Boehringer Ingelheim (Ofev) and Roche (Esbriet).
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive, focusing on the development of new therapies for various diseases. It's driven by technological advances, regulatory changes, and the increasing need for innovative treatments.
Positioning
MediciNova focuses on niche markets with significant unmet needs. Their competitive advantage lies in repurposing existing drugs for new indications, which potentially reduces development time and cost.
Total Addressable Market (TAM)
The total addressable market for neurodegenerative diseases, inflammatory diseases, and cancer is substantial, estimated to be hundreds of billions of dollars. MediciNova is positioned to capture a portion of these markets with successful drug approvals, focused on specific subtypes of diseases.
Upturn SWOT Analysis
Strengths
- Proprietary drug candidates with potential for multiple indications
- Experienced management team
- Established research and development capabilities
- Repurposing strategy potentially reduces development costs and timelines
Weaknesses
- Limited financial resources compared to larger pharmaceutical companies
- Dependence on successful clinical trial outcomes
- No currently marketed products
- High risk associated with drug development
Opportunities
- Potential for regulatory approvals and commercialization of drug candidates
- Partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Orphan drug designations for rare diseases
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other pharmaceutical companies
- Patent expirations
- Generic competition
Competitors and Market Share
Key Competitors
- AMLY
- VRCA
- BIIB
- RHHBY
- MRK
Competitive Landscape
MediciNova faces strong competition from larger, well-established pharmaceutical companies. Its advantage lies in its focus on specific unmet needs and its drug repurposing strategy, although its unproven clinical success is its weakness.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily driven by progress in clinical trials and licensing agreements.
Future Projections: Future growth depends on successful clinical trial outcomes and regulatory approvals. Analyst estimates vary significantly.
Recent Initiatives: Recent initiatives include advancing clinical trials for MN-166 in ALS and PMS and MN-001 in IPF and NASH.
Summary
MediciNova is a biopharmaceutical company focusing on developing novel treatments, especially for neurological disorders and inflammatory diseases. While its drug repurposing strategy offers potential cost and time savings, the company is currently pre-revenue, relying on clinical trial success and further funding. The main threats come from regulatory hurdles, competition, and potential clinical trial failures. Success hinges on achieving positive clinical trial results and securing regulatory approvals for its key drug candidates.
Peer Comparison
Sources and Disclaimers
Data Sources:
- MediciNova's website
- SEC filings
- Analyst reports (where available)
- Industry reports
Disclaimers:
This analysis is based on available information and is not financial advice. The biopharmaceutical industry is inherently risky, and future results may differ significantly from current expectations.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About MediciNova Inc
Exchange NASDAQ | Headquaters La Jolla, CA, United States | ||
IPO Launch date 2005-02-08 | Co-Founder, President, CEO & Chairman Dr. Yuichi Iwaki M.D., Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 13 | Website https://medicinova.com |
Full time employees 13 | Website https://medicinova.com | ||
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and substance dependence and addiction, as well as prevention of acute respiratory distress syndrome, and long COVID. It is also developing MN-001 (tipelukast), an orally bioavailable small molecule compound in Phase 2 clinical trial to treat fibrotic and other metabolic disorders, including nonalcoholic fatty liver disease and hypertriglycedemia. The company has a license agreement with Kyorin Pharmaceuticals for the development and commercialization of MN-166 and MN-001. MediciNova, Inc. was incorporated in 2000 and is headquartered in La Jolla, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.